All Stories

  1. HLA-DRB1*01:03 in patients with inflammatory bowel disease: a genotype–phenotype association study
  2. FP22 Impact of implementing a pharmacist-led selective JAK1 inhibitor clinic on IBD care: a retrospective pre-post study
  3. Expert recommendations for the management of faecal incontinence in systemic sclerosis: a report from the World Scleroderma Foundation gastrointestinal ‘ad hoc committee’
  4. Expert recommendations for the management of refractory gastro-oesophageal reflux disease in systemic sclerosis: a report from the World Scleroderma Foundation (WSF) Gastrointestinal ‘Ad hoc committee’
  5. OA10 Using single-cell technology to understand the cellular landscape of colonic disease in systemic sclerosis
  6. Associations between demographic, clinical and dietary factors and flares in inflammatory bowel disease: the PRognostic effect of Environmental factors in Crohn’s and Colitis (PREdiCCt) prospective cohort study
  7. P1120 Impact of Implementing a Pharmacist-Led Selective JAK1 Inhibitor Clinic on IBD Care: A Retrospective Pre-Post Study
  8. Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use
  9. Delivering a Modified Mindfulness Based Stress Reduction Intervention for Inflammatory Bowel Disease in Adolescents and Young Adults: Assessing Feasibility, Acceptability, and Effectiveness
  10. Zenker peroral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch: a multicentre retrospective cohort study
  11. P170 Zenker peroral endoscopic myotomy (Z-POEM) is a safe and feasible alternative first-line treatment for zenker’s diverticulum
  12. ABS0165 PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF FECAL INCONTINENCE IN SYSTEMIC SCLEROSIS: A REPORT FROM WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL “AD HOC COMMITTEE”
  13. OP0121 PROVISIONAL EXPERT RECOMMENDATIONS FOR THE MANAGEMENT OF REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE IN SYSTEMIC SCLEROSIS: A REPORT FROM THE WORLD SCLERODERMA FOUNDATION (WSF) GASTROINTESTINAL “AD HOC COMMITTEE”
  14. Endoscopic Suturing for Defect Closure in the Upper Gastrointestinal Tract: A Retrospective Cohort Study
  15. Targeted screening of at-risk patients with chronic heartburn using a non-endoscopic capsule sponge device can enhance the detection of Barrett’s oesophagus
  16. Oesophageal pH testing: everything you wanted to know but were too afraid to ask
  17. Systemic sclerosis–related fecal incontinence: a scoping review focusing on a neglected manifestation
  18. A multimodal endoscopic approach for esophageal fistula closure
  19. The A to Z of Peroral Endoscopic Myotomy
  20. S1537 Radiofrequency Vapor Ablation is Safe and Well-Tolerated for Duodenal Mucosal Ablation in the Treatment of Type 2 Diabetes: Six Month Results From the First-in-Human Dose Finding Study
  21. Cough and gastro-esophageal reflux in systemic sclerosis-associated ILD:a prospective study
  22. The safety and efficacy of endoscopic approaches for the management of Zenker’s diverticulum: a multicentre retrospective study
  23. A disease-associated gene desert directs macrophage inflammation through ETS2
  24. Endoscopic suturing and clipping devices for defects in the GI tract
  25. P172 A comparison of the safety and efficacy of flexible versus rigid endoscopic approaches for the management of zenker’s diverticulum
  26. P223 Evaluation of the safety and efficacy of transoral incisionless fundoplication (TIF2.0) for gastro-oesophageal reflux disease: a UK cohort study
  27. P262 Performance of endoscopic approaches for the treatment of Zenker’s diverticulum: a systematic review and meta-analysis
  28. P272 Safety and efficacy of cryoablation for the treatment of Barrett’s oesophagus: a systematic review and meta-analysis
  29. P152 Safety and efficacy of endoscopic vacuum therapy for the management of leaks following bariatric surgery: a systematic review and meta-analysis
  30. P221 Zenker per-oral endoscopic myotomy (Z-POEM) is safe and effective for the management of pharyngeal pouch
  31. A MULTICENTRE RETROSPECTIVE COHORT STUDY TO COMPARE THE SAFETY AND EFFICACY OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY, FLEXIBLE DIVERTICULOTOMY, AND RIGID DIVERTICULOTOMY FOR THE MANAGEMENT OF ZENKER’S DIVERTICULUM
  32. A MULTICENTRE RETROSPECTIVE COHORT STUDY TO COMPARE THE SAFETY AND EFFICACY OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY, FLEXIBLE DIVERTICULOTOMY, AND RIGID DIVERTICULOTOMY FOR THE MANAGEMENT OF ZENKER’S DIVERTICULUM
  33. PERFORMANCE OF ENDOSCOPIC APPROACHES FOR ZENKER DIVERTICULUM MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
  34. PERFORMANCE OF ENDOSCOPIC APPROACHES FOR ZENKER DIVERTICULUM MANAGEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
  35. SAFETY AND EFFICACY OF CRYO-ABLATION ON BARRETT ESOPHAGUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
  36. SAFETY AND EFFICACY OF CRYO-ABLATION ON BARRETT ESOPHAGUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
  37. THE UK EXPERIENCE OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY (Z-POEM) FOR THE TREATMENT OF ZENKER’S DIVERTICULUM
  38. THE UK EXPERIENCE OF ZENKER PER-ORAL ENDOSCOPIC MYOTOMY (Z-POEM) FOR THE TREATMENT OF ZENKER’S DIVERTICULUM
  39. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial
  40. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study
  41. P135 Association of Serum Anti-Muscarinic 3 Antibodies with Gastrointestinal Disease in Systemic Sclerosis
  42. A multicentre retrospective cohort study to compare the safety and efficacy of zenker per-oral endoscopic myotomy, flexible diverticulotomy, and rigid diverticulotomy for the management of zenker’s diverticulum
  43. Endoscopic suturing for defect closure in the upper gastrointestinal tract: a retrospective cohort study
  44. Performance of endoscopic approaches for Zenker diverticulum management: a systematic review and meta-analysis
  45. Safety and efficacy of cryo-ablation on Barrett esophagus: a systematic review and meta-analysis
  46. The UK experience of zenker per-oral endoscopic myotomy (z-poem) for the treatment of zenker’s diverticulum
  47. The safety and efficacy of endoscopic vacuum therapy for the management of leaks following bariatric surgery: A systematic review and meta-analysis
  48. Role of oesophageal balloon cryoablation in combination with personalised immunotherapy to achieve luminal control in metastatic oesophageal cancer: a case report
  49. The endoscopic management of oesophageal strictures
  50. Metabolic Endoscopy: Should Gastroenterologists Be Treating Type 2 Diabetes?
  51. Peroral endoscopic myotomy for the management of symptomatic cricopharyngeal bar (C-POEM): a case series and video demonstration
  52. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
  53. Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn’s Disease Patients
  54. Symptomatic duodenal metastasis from a small cell lung cancer primary: a rare case
  55. Metabolic and Bariatric Endoscopy: A Mini-Review
  56. Management of a large percutaneous endoscopic gastrostomy tube-associated gastric ulcer with endoscopic suturing
  57. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom
  58. Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn’s Disease
  59. A disease-associated gene desert orchestrates macrophage inflammatory responses via ETS2
  60. Phenome-Wide Association Study of Drugs and Co-morbidities Associated with Gastrointestinal Dysfunction in Systemic Sclerosis
  61. Genome-Wide Methylation Profiling in 229 Patients With Crohn’s Disease Requiring Intestinal Resection: Epigenetic Analysis of the Trial of Prevention of Post-operative Crohn’s Disease (TOPPIC)
  62. Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a pr...
  63. Between progress and changing times: The journey of UEG Education Committee's chair
  64. Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID ‐19 pandemic: the PREPARE‐IBD multicentre cohort study
  65. Blood and guts
  66. Proton pump inhibitors in systemic sclerosis: a reappraisal to optimise treatment of gastro-oesophageal reflux disease
  67. Diagnostic Performance of Magnetic Resonance Enterography Disease Activity Indices Compared with a Histological Reference Standard for Adult Terminal Ileal Crohn’s Disease: Experience from the METRIC Trial
  68. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
  69. Comparative effectiveness of a second-line biologic in patients with ulcerative colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
  70. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in infliximab- and vedolizumab-treated patients
  71. The Relationship Between Mucosal Microbiota, Colitis, and Systemic Inflammation in Chronic Granulomatous Disorder
  72. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
  73. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
  74. PMO-29 Switching between infliximab biosimilars: experience from two inflammatory bowel disease centres
  75. PMO-33 Infliximab biosimilar switching – can you switch more than once?
  76. PMO-50 Factors independently associated with fatigue in IBD: results from the PREdiCCt study
  77. Benefits of Structured Pediatric to Adult Transition in Inflammatory Bowel Disease
  78. Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients
  79. The relationship between mucosal microbiota, colitis and systemic inflammation in Chronic Granulomatous Disorder
  80. Autoantibody predictors of gastrointestinal symptoms in systemic sclerosis
  81. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab
  82. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study
  83. Endoscopy during the peak of COVID-19 pandemic: impact on activity and financial implications for a tertiary referral center in London
  84. Editorial: fatigue—difficult to assess and difficult to treat
  85. Constipation, Bloating and Abdominal Pain
  86. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn’s disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource
  87. UEG Guidelines framework to guide clinical practice
  88. Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic
  89. Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
  90. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic
  91. P156 Understanding the associations and impact of severe gastrointestinal involvement in systemic sclerosis: a structured approach
  92. The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy
  93. UEG Education—building on success
  94. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
  95. P738 Real world outcomes on the efficacy and safety of combination of biologic and immunosuppressive therapy in liver transplant recipients with inflammatory bowel disease
  96. Diagnosis and management of bile acid diarrhoea: a survey of UK expert opinion and practice
  97. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study
  98. IBD BioResource: an open-access platform of 25 000 patients to accelerate research in Crohn’s and Colitis
  99. Chronic Granulomatous Disorder–Associated Colitis Can Be Accurately Evaluated with MRI Scans and Fecal Calprotectin Level
  100. PTH-039 The cost-effectiveness of radiofrequency ablation for gastric antral vascular ectasia refractory to first-line endoscopic therapy
  101. Editorial: combination immunosuppressive therapy to treat Crohn’s disease - ready for all age groups?
  102. Radiological findings in gastrointestinal scleroderma
  103. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study
  104. Cause or effect? Interpreting emerging evidence for dysbiosis in systemic sclerosis
  105. Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease
  106. Radiofrequency ablation for patients with refractory symptomatic anaemia secondary to gastric antral vascular ectasia
  107. In memory of Dr Tomer Adar
  108. A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population
  109. Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel disease
  110. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden
  111. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial
  112. 118 ENDOSCOPIC RADIOFREQUENCY ABLATION IS AN EFFECTIVE THERAPY IN PATIENTS WITH SYMPTOMATIC ANAEMIA SECONDARY TO GASTRIC ANTRAL VASCULAR ECTASIA
  113. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Pilot Study of Cannabidiol-rich Botanical Extract in the Symptomatic Treatment of Ulcerative Colitis
  114. Editorial: anti-TNF therapy and myopenia in Crohn's disease-another step towards personalised medicine
  115. There is a need for new systemic sclerosis subset criteria. A content analytic approach
  116. PTH-041 Definitive management of a very rare cause of significant acute upper gastrointestinal bleeding: gastric lipoma resected by hybrid endoscopic submucosal dissection
  117. PTH-054 Endoscopic submucosal dissection (esd) of gastric and rectal neuroendocrine tumours (nets): a case series from a tertiary referral centre (with video)
  118. AODTU-001 Radiofrequency ablation in patients with symptomatic anaemia secondary to gastric antral vascular ectasia
  119. Structured Transition Enhances Clinical Outcome without an Increase in Healthcare Cost in Adolescent Patients with IBD: the UK Transit Study
  120. The Impact of Transition to Adult Gastroenterology Services on Health-Related Quality of Life in Young Adult Patients with IBD: The UK Transit Study
  121. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care
  122. P363 The impact of transition to adult gastroenterology services on health-related quality of life in young adult patients with IBD: the UK TRANSIT study
  123. P543 Structured transition enhances clinical outcome without an increase in healthcare cost in adolescent patients with IBD: the UK TRANSIT study
  124. Small bowel obstruction caused by a migrated Obalon gastric bariatric balloon: nonsurgical management by antegrade double-balloon panenteroscopy
  125. Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial
  126. The role of dietary supplements in inflammatory bowel disease
  127. Small and Large Intestinal Involvement and Nutritional Issues
  128. Gallstone mimicry: a rare cause of abdominal pain
  129. Gastrointestinal manifestations of systemic sclerosis
  130. The ABC of E-learning: Utilizing E-learning resources for training and research in gastroenterology
  131. Elevated liver enzymes in inflammatory bowel disease
  132. Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis
  133. P.14.3 CORRELATION BETWEEN CLINICAL RESPONSE AND ANEMIA RESOLUTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES TREATED WITH ANTI-TNF INHIBITORS
  134. Endoscopic resection of a giant ileal inflammatory fibroid polyp by retrograde double-balloon enteroscopy
  135. Clinical Features and HLA Association of 5-Aminosalicylate (5-ASA)-induced Nephrotoxicity in Inflammatory Bowel Disease
  136. P32 Role of non acid and proximal reflux in scleroderma-associated interstitial lung disease
  137. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs
  138. OP-16 DIETARY INTERVENTION USING THE LOW FODMAP DIET VERSUS THE “MILK, EGG, WHEAT AND SOYA FREE” DIET FOR TREATMENT OF FUNCTIONAL GUT DISORDERS A SINGLE CENTRE EXPERIENCE
  139. Gastro-oesophageal dismotility measurements in scleroderma-associated interstitial lung disease: Correlation with respiratory and reflux symptoms
  140. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis
  141. Intractable diarrhoea despite immune reconstitution in an HIV positive man
  142. UEG E‐learning: The future has arrived
  143. 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada
  144. Indurated plaques on the penis
  145. Gut symptoms in diabetics correlate with components of the rectoanal inhibitory reflex, but not with pudendal nerve motor latencies or systemic autonomic neuropathy
  146. PTH-056 Trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis
  147. AB0727 There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach
  148. OC-055 ‘ibdpassport’: evaluating the quality of an internet-based travel resource for inflammatory bowel disease
  149. PTH-072 Diagnostic yield of mr enterography versus wireless video capsule endoscopy in suspected small bowel paediatric crohn’s disease
  150. Hepatic portal venous gas and portal venous thrombosis following colonoscopy in a patient with terminal ileal Crohn's disease
  151. Irritable bowel syndrome
  152. Travel health and pretravel preparation in the patient with inflammatory bowel disease
  153. Sa1264 A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centred Pilot Study to Assess the Symptomatic Treatment of Ulcerative Colitis With Cannabidiol
  154. Sa1127 Cutaneous Events During Anti-Tumour Necrosis Factor (Anti-TNF) Treatment at a London Inflammatory Bowel Disease (IBD) Centre
  155. Sa1373 Significant Findings From a Randomised Control Trial of Posterior Tibial Nerve Stimulation in Systemic Sclerosis Associated Faecal Incontinence
  156. Tu1079 ‘IBDpassport’: Evaluating the Quality of an Internet-Based Travel Resource for Inflammatory Bowel Disease
  157. Tu1080 A Single-Centre Pilot Study Examining Internet Use for Health-Related Information Among Patients With Inflammatory Bowel Disease
  158. A rare cause of abdominal pain, diarrhoea and GI bleeding
  159. UEG Education: time to shape the future
  160. P-057: A nurse-led tertiary adolescent IBD clinic: 12 month trial and exploration of patient satisfaction
  161. P-114: Response to exclusive enteral nutrition (EEN) in adolescent patients with newly diagnosed Crohn’s disease (CD)
  162. P-115: Thiopurine metabolite (TM) monitoring in adolescent IBD (aIBD): Poor adherence is common
  163. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in tho...
  164. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis
  165. OC-055 Ibd Passport-developing An Evidence-based Internet Travel Resource For Inflammatory Bowel Disease: A Report Of The Initial Stages Of Implementation
  166. PTU-092 Patient And Professionals Perceptions Of Travel Behaviour In Inflammatory Bowel Disease
  167. PWE-115 Patients Continue To Travel Abroad Despite Recently Active Disease And Travel Concerns: Results Of A Single Centre Study In Inflammatory Bowel Disease And Travel
  168. PWE-183 Preliminary Significant Findings From A Randomised Control Trial Of Posterior Tibial Nerve Stimulation In Systemic Sclerosis Associated Faecal Incontinence
  169. PTH-044 A Single-centre Pilot Study Examining Internet Use For Health Related Information Among Patients With Inflammatory Bowel Disease
  170. Mo2015 Preliminary Significant Findings From a Randomised Control Trial of Posterior Tibial Nerve Stimulation in Systemic Sclerosis Associated Faecal Incontinence
  171. Su1095 A Recent Flare of Disease Does Not Prohibit Travel: Early Results of a Single Centre Study in Inflammatory Bowel Disease and Travel
  172. Tu1275 Prevalence, Type, and Management of Anaemia in Patients Presenting With Congestive Cardiac Failure
  173. P574 A recent flare of disease does not prohibit travel: early results of a single centre study in inflammatory bowel disease and travel
  174. P553 A single-centre pilot study examining internet use for health related information among patients with inflammatory bowel disease
  175. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  176. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  177. Bloody Diarrhoea
  178. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy
  179. PTH-132 Iron Deficiency Anaemia Nurse Led Clinic: Audit of 1st Year
  180. PTH-100 Psychological Morbidity and Provision of Psychological Support in the Inflammatory Bowel Disease Clinic
  181. PTH-112 Infliximab Promotes Steroid free Remission in Patients with Chronic Active Ulcerative Colitis– a UK Single Centre Experience
  182. PTH-113 Clinical Response to Induction Anti-Tnf Therapy has no Effect on Haemoglobin Levels in Patients with IBD
  183. PTH-114 Skin Pathology Associated with Anti-Tumour Necrosis Factor (ANTI-TNF) Therapy- a Single UK IBD Centre Experience
  184. P366 Skin pathology associated with anti-tumournecrosis factor (anti-TNF) therapy – a single UK IBD centre experience
  185. P57 Comparative Cost-Effectiveness of IGRA to Detect Latent TB Infection in UK Inflammatory Bowel Disease Patients Initiating Anti-TNFα Agents: Abstract P57 Table 1
  186. Weight loss and lumbosacral back pain in a 79-year-old Indian man
  187. Malignant mimicry—a 17-year-old with abdominal pain and weight loss
  188. PTU-113 Quality of life in patients with ileoanal pouch: a survey comparing two different patient populations
  189. PTU-096 The use of commercial interferon-γ release assays to screen for mycobacterial infection in inflammatory bowel disease patients initiating anti-TNF agents
  190. Do We Do Enough to Convince Our Patients With Crohn's Disease to Stop Smoking? Results From a North London Audit
  191. Influence of Smoking and Other Environmental Factors in Inflammatory Bowel Disease Activity: What Do Our Patients Think?
  192. Irritable bowel syndrome
  193. Tu1576 Capsule Endoscopy for Obscure Occult Gastrointestinal Bleeding: Incidence of Pathology Detected Within Reach of a Standard Gastroscope
  194. Influence of smoking and other environmental factors in inflammatory bowel disease activity: what do our patients think?
  195. Iron deficiency anaemia is common in patients with an ileoanal pouch and is not always associated with inflammation
  196. There will be blood... a complete audit cycle
  197. Images of the terminal ileum are more convincing than cecal images for verifying the extent of colonoscopy
  198. Attitudes and Experiences of Adolescents in an Innovative IBD Transition Service
  199. T1272 Screening Patients Initiating Anti-TNF Agents for Mycobacterial Infection Using Interferon-Gamma Release Assays (IGRA): the Experience of a Large Inflammatory Bowel Disease Service
  200. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome
  201. The effect of Khat (Catha edulis) as an appetite suppressant is independent of ghrelin and PYY secretion
  202. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease
  203. Gastrointestinal Manifestations of Systemic Sclerosis
  204. Pharmacological modulation of gut mucosal and large vessel blood flow
  205. Reaping value from intellectual property: DuPont's strategic approach achieves global growth
  206. Ghrelin augments afferent response to distension in rat isolated jejunum
  207. The effect of different macronutrient infusions on appetite, ghrelin and peptide YY in parenterally fed patients
  208. Diabetes and the Gastrointestinal System
  209. Prokineticin-2, motilin, ghrelin and metoclopramide: Prokinetic utility in mouse stomach and colon
  210. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double blind, placebo controlled, crossover study
  211. Effect of acute physical and psychological stress on gut autonomic innervation in irritable bowel syndrome
  212. Sporadic duodenal adenoma is associated with colorectal neoplasia
  213. Ghrelin for the gastroenterologist: history and potential
  214. Biofeedback, not laxatives, improves symptoms, transit and autonomic tone in functional constipation
  215. Medical management of diverticular disease
  216. Colonic Disorders